Bemarituzumab - Amgen
Alternative Names: AMG-552; Anti-FGFR2b antibody - Five Prime Therapeutics; FPA-144Latest Information Update: 03 Jul 2024
At a glance
- Originator Galaxy Biotech
- Developer Amgen; Five Prime Therapeutics; ZAI Lab
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Phase I/II Solid tumours
- Phase I Non-small cell lung cancer
Most Recent Events
- 28 May 2024 Amgen completes a phase I trial in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA, Spain, Poland, Japan, Belgium, France, Taiwan and South Korea (IV) (NCT05267470)
- 08 Feb 2024 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease, Metastatic disease) in Argentina, Brazil, Finland, Italy, Romania (IV) (NCT05325866)
- 08 Feb 2024 Phase-III clinical trials in Gastric cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Switzerland, Hong Kong, Czech Republic, Chile, Bulgaria, Austria, Romania (IV) (NCT05111626)